Jincheng Pharma

Shandong Jincheng Pharmaceutical Group Co., Ltd. was established in 2004, headquartered in Zibo City, Shandong Province. It was listed on the ChiNext board of the Shenzhen Stock Exchange in 2011 (stock code: SZ300233). As a national high-tech enterprise, it currently employs over 3,300 people and has more than 30 holding and participating companies globally. The company primarily engages in the research, development, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), drug formulations, and health products. It is a major global production and research base for cephalosporin side-chain intermediates and the bio-fermented API glutathione, and a well-known domestic manufacturer of anti-infective and gynecological preparations, with a rich product line of cephalosporin antibiotics and full-lifecycle gynecological products in China. It is an emerging, internationally oriented, innovative pharmaceutical and health industry group with an integrated industrial chain covering research, production, and sales.
Adhering to the strategic development positioning of basing on the broader pharmaceutical industry and expanding into the health sector, the company currently has products in multiple therapeutic areas including anti-infection, gynecology, antiviral, chronic diseases, pediatrics, hormones and immunomodulation, and liver diseases. It holds over 80 drug and health product registration approvals, including chemical APIs, injections, tablets, capsules, soft capsules, powders, sprays, and creams, supported by ten major production bases in Beijing, Shanghai, Guangzhou, and Shandong. The company has created several well-known branded products in the industry. It has established long-term cooperation with over a hundred pharmaceutical companies worldwide, forming a global market layout with the domestic market as the main body, Europe, America, and India as primary export destinations, and radiating to Japan, South Korea, and ASEAN markets. It provides pharmaceutical and health products to more than 30 countries and regions and over 3,000 domestic medical institutions and chain pharmacies. Every year, hundreds of millions of patients regain health through the use of Jincheng Pharmaceutical products. The company has won over 300 honors, including the National Science and Technology Progress Award, and has been selected into the FTSE Russell Index, ranking among the "Double Top 100" of China's pharmaceutical industry and China's pharmaceutical manufacturing industry.
In the future, the company will adhere to the overall strategy of "focusing on the main business, aggregating resources, and concentrating on innovation," centered on meeting customer and clinical needs. It will focus on high-end medical chemical products, high-barrier specialty APIs and bioactive products, high-level generics, and improved innovative drugs, expand CMO/CDMO business, actively explore the innovative drug field, enhance the innovation system across the entire industrial chain, and innovate new models of pharmaceutical R&D and manufacturing, striving to build the enterprise into a globally renowned innovative pharmaceutical and health group.